Introduction

CD4
Up to a few years ago the catecholamines dopamine (DA), norepinephrine (NE) and epinephrine (E) were considered mainly as conventional neurotransmitters and neuroendocrine mediators, however there is now robust evidence that they are produced and utilized also by cells of the immune system. [6] [7] [8] [9] [10] [11] [12] [13] [14] Over the last decade, data have been accumulating about the functional relevance of the endogenous production of catecholamines in immune system cells. 7, 15 We have recently shown that in human peripheral blood mononuclear cells stimulated with the T-cell preferential polyclonal mitogen phytohaemagglutinin (PHA) the synthesis of catecholamines is effectively induced through a protein kinase C-dependent mechanism which triggers the de novo expression of the mRNA for tyrosine hydroxylase (TH, EC 1.14.16.2, the first and rate-limiting enzyme in the synthesis of catecholamines) and its subsequent activation in T and B lymphocytes, resulting in intracellular accumulation of substantial amounts of such mediators. 16, 17 In these conditions, pharmacological inhibition of TH results in decreased activation-induced apoptosis, 18 supporting a role for endogenous catecholamines in the functional modulation of lymphocyte activation. Intracellular catecholamines accumulating in activated lymphocytes are nonetheless also likely to provide these cells with a supply of mediators, which in turn may act upon lymphocytes themselves and/or upon neighbouring cells. 19 For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From Lymphocytes are indeed a privileged target for catecholamines, inasmuch as they both express adrenoceptors (AR) 20, 21 and dopaminergic receptors. [22] [23] [24] [25] [26] NE released from sympathetic nerve terminals in lymphoid organs is widely accepted as a key mediator in the interplay between the brain and the immune system. 21 In particular, functional β 2 -ARs expressed on immune cells regulate CD4+ T cell-mediated immunity as well as antibody production by B cells (recently reviewed in 27). DA, on the other side, has been only recently identified as a direct modulator of the immune response. 28 Nonetheless, over the last few years evidence has rapidly increased regarding the ability of DA to affect the function of lymphocytes, 22, [24] [25] [26] 29, 30 including murine Treg. 31 Evidence thus supports the existence in lymphocytes of an endogenous catecholaminergic system.
Interestingly, following cellular activation the various components of the system seem to undergo up-regulation, including: de novo expression of functional α 1 -ARs, 32 increased expression of β-ARs, 33 increased response to DA (through D3 receptors), 24 and increased TH expression and accumulation of catecholamines. 16 Up-regulation of the endogenous catecholaminergic system in activated lymphocytes, together with the notion that Treg express the general phenotype of activated cells, led us to hypothesize that Treg could possess an array of functional catecholamine receptors, constitutively express TH and consequently contain amounts of catecholamines signficantly higher than naïve Teff. The present study was therefore undertaken to test such hypothesis, and to investigate the possible role of endogenous catecholamines in the functional modulation of human Treg.
Materials and methods
Substances
The following substances were purchased from Sigma (St. Louis, MO, USA): dopamine (DA) 
Purification of human Treg and Teff
Treg and Teff were isolated from buffy coat preparations derived from the whole blood of healthy donors by immunomagnetic sorting using the Dynal CD4 + CD25 + Treg Kit (Dynal A.S., Oslo, Norway), according to the manufacturer's instructions. Both Treg and Teff were finally free from residual beads (as assessed by electron microscopy), their purity was always greater than 95% by flow cytometry, and their vitality was greater than 99% by the Trypan Blue exclusion test. The artificial activation of the cells was excluded by cytofluorimetric analysis of surface expression of CD69, which was always <1%. For subsequent culture, cells were resuspended in RPMI 1640 medium supplemented with 10% heath-inactivated FCS, 2 mM glutamine and 100 U/ml penicillin/streptomycin, at the final concentration of 1x10 6 cells/ml, and incubated at 37°C in a moist atmosphere of 5% CO 2 .
High performance liquid chromatography (HPLC) with multi-electrode electrochemical detection
Catecholamines in the cells and in the culture medium were assayed by high performance liquid chromatography with multi-electrode electrochemical detection (HPLC-ED). To this end, 1x10 6 cells were processed as described previously, 14 and 30 µl of the recovered supernatant were injected into the chromatographic system. The medium was added with HClO 4 0,4 N (1:1 v/v), kept on ice for 30 min, and then centrifuged for 5 min at 15,000 g and 20°C. Again, the supernatant was recovered, filtered and 30 µl were injected into the HPLC system. The system consisted of a dualpiston pump (model LC10ADVP, Shimadzu, Kyoto, Japan), a Beckman Ultrasphere IP C 18 NE, E, the DA metabolites DOPAC, 3-MT and HVA, the NE metabolites MHPG, DHPG, VMA and NM, and the E metabolite MET. The chromatograms were collected, stored and processed with the application software Coularray for Windows (ESA). Catecholamines and metabolites in the samples were quantified by using the peak heights of a standard curve generated by injecting known samples (3 fmol-3 pmol), and values were finally normalized for cell number. By use of this method, the lowest amounts of catecholamines and metabolites which could be assayed were 0.02-0.10 x 10 -12 mol/10 6 cells or /mL. 
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Flow cytometric analysis of dopamine receptors on Teff and Treg
Freshly isolated Teff and Treg were subjected to an indirect immunofluorescence staining, using rabbit polyclonal IgG directed against human dopaminergic D1-like (D1 and D5) and D2-like (D3, D4 and D5) receptors. Briefly, 1x10 6 cells were incubated with each antibody at 1:25 dilution in 100 µL for 30 min on ice. Cells were then resuspended in 100 µL PBS and stained with a FITCconjugated goat anti-rabbit IgG antibody (10 µL at 1:10 dilution). In each analysis, samples of the same specimens were stained with the secondary antibody alone (negative control) to assess nonspecific fluorescence intensity values. For personal use only. on September 13, 2017. by guest www.bloodjournal.org From
Statistics
Data are presented as means±SD, with n indicating the number of observations. Statistical significance of the differences between groups was assessed by two-tailed Student's t test or oneway analysys of variance followed by Bonferroni or Dunnet post test for paired or unpaired data, as appropriate. Calculations were performed using a commercial software (GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, CA, USA).
Results
Treg cells contain high levels of intracellular catecholamines and express tyrosine hydroxylase, vesicular monoamine transporters, dopaminergic receptors and adrenoceptors
In human Treg, HPLC-ED analysis detected DA, NE and E, together with their common precursor L-DOPA and several of their major metabolites ( Fig. 1) . In comparison to Teff, in Treg both L-DOPA and metabolite levels were similar, however DA, NE and E were significantly higher (Table   2) , from 19-fold (in the case of NE), to 83-(as for E) and even 170-fold (as in the case of DA), and reached values which are very close to those which we previously reported to occur in human lymphocytes after mitogen activation. 16 Treg also expressed the mRNA for TH, the rate-limiting enzyme in the synthesis of catecholamines, for vesicular monoamine transporters (VMAT) 1 and 2
( Fig. 2) , and the mRNAs for D2, D3, D4, and D5 dopaminergic receptors, as well as for α 1 -, and β 1 -and β 2 -adrenoceptors (ARs) ( 15.6% of Teff and 11.6% of Treg, and in these latter cells receptor density was also significantly lower than those of D1 in Teff or of D3 and D5 in Treg (Table 2) .
Reserpine induces the release of catecholamines from Treg
The intracellular levels of catecholamines and of their metabolites did not differ in freshly isolated
Treg and in Treg cultured for 30 min (data shown in Table 3 and 4). Only DOPAC levels increased from 0,21±0,26 10 -12 mol/10 6 cells (n = 6) to 0.54±0,08 10 -12 mol/10 6 cells (n = 6) (P<0.05). As shown in Fig. 5 and in Table 4 , 1-h incubation of Treg with reserpine 1 µM (an agent which inhibits the uptake of catecholamines into chromaffin granules) induced a huge decrease of intracellular catecholamines, without affecting their metabolites, with the exceptions of the NE metabolite MHPG, which increased. The decrease was likely due to an overflow of catecholamines from the cells, as suggested by the concurrent increase of DA, NE and E in the medium, where also the NE metabolite NM increased while the DA metabolite 3-MT decreased (Table 4) . When the total content per well (i.e., cells+medium) of each catecholamine and metabolite was considered in the absence and in the presence of reserpine, as shown in the right-side columns of Table 4 , it became evident that treatment with reserpine induced an overall increase of DA and E, as well as of the NE metabolite MHPG, and a decrease of the DA metabolite 3-MT. reduction of mitogen-induced production of TNF-α and interferon (IFN)-γ, however incubation with reserpine did not modify this effect (Table 5) . In separate experiments, reserpine did not affect the percentage of viable cells in cultured Treg and Teff, alone and together, at rest and after mitogen stimulation (data not shown).
Incubation of Treg/Teff co-culture with reserpine impairs the suppression exerted by Treg on the proliferation, but not cytokine secretion, of Teff
Dopaminergic D1/D5 receptor pathways mediate reserpine-induced suppression of Treg function
To assess whether the observed effect of reserpine was exerted through dopaminergic receptorand/or AR-mediated pathways, the co-cultures of Treg with Teff were incubated with reserpine 1 µM alone or in the presence of antagonists selective for D2, D3, D4 or D5 dopaminergic receptor subtypes or for α 1 -, β 1 -, β 2 -ARs, i.e. all the catecholamine receptors which were found to be expressed in Treg (see above). As shown in Fig. 6 , the effect of reserpine was completely reverted only in the presence of the D1/D5 selective antagonist SCH 23390, while none of the other antagonists had any significant effect. In separate experiments, SCH 23390 1 µM alone had no effect per se on either Treg or Teff viability, or on mitogen-induced proliferation of Teff (data not shown).
Dopaminergic D1/D5 receptors are functionally coupled to adenylate cyclase, 34 and therefore, to investigate their function, intracellular cAMP levels were measured in Teff and in Treg in the absence and in the presence of DA. As shown in Fig. 7 , cAMP levels were similarly low in both
Treg and Teff, and incubation with DA had no effect in Teff but induced a huge and sustained increase of intracellular cAMP in Treg, which was already evident at 5 min and could be detected 
Effect of reserpine on IL-10 and TGF-β production by Treg and Teff and on FoxP3 mRNA expression in Treg
As shown in Table 6 , both Treg and Teff produced IL-10 and TGF-β, however production of both cytokines was higher in Treg than in Teff. Production of IL-10 and TGF-β in Teff was not affected by reserpine, but in Treg it was significantly reduced, both at the mRNA and at the protein level (Table 6 and Fig. 8 ). As in the case of reserpine-induced reduction of the suppressive effect of Treg, also reserpine-induced inhibition of IL-10 and TGF-β production was selectively reverted by pharmacological blockade of the D1/D5 receptor pathways, but not by blockade of α 1 -, β 1 -, β 2 -AR pathways (Fig. 8 ). FoxP3 mRNA was not detected in Teff, while in Treg its levels were 0.55±0.09
(n = 9) and were not affected to any significant extent by reserpine 1 µM (0.48±0.14, n = 9;
P>0.05).
Discussion
The main finding of the present study is that human Treg selectively express TH, the key enzyme in the synthesis of catecholamines, and contain high amounts of catecholamines stored in reserpinesensitive compartments, which, upon release, subserve an autocrine/paracrine modulatory loop leading to impaired suppressive activity of Treg towards mitogen-induced Teff proliferation.
Pharmacological evidence indicates that functional impairment of Treg depends upon the activation of dopaminergic D1-like receptors pathways, and is due to inhibition of both IL-10 and TGF-β production by these cells.
Endogenous catecholamines in human Treg and Teff
Although trace amounts of catecholamines are usually detected in naive lymphocytes, 11 we previously reported that mitogen stimulation is needed to trigger the espression of TH and the subsequent synthesis of DA, NE, and E, 16 up to amounts which are able to affect lymphocyte function to a significant extent. 18 Expression of TH and high intracellular levels of catecholamines Human Teff, on the other side, contain only trace amounts of catecholamines which, due to their paucity, are unlikely to succeed in subserving any autocrine/paracrine regulatory loop, as indicated by the lack of effect of reserpine on IL-10 and TGF-β production in these cells. This is also in line with previous observations showing that only high intracellular levels of catecholamines occurring after lymphocyte activation are able to affect survival and death in these cells. Table 2 ). Both the percentage of positive cells as well as receptor density per cell were similar in Treg and Teff (with the only notable exception of D1 receptors on Treg, which were expressed to a very limited extent). This finding was surprising, as in our experiments Treg and Teff clearly differ in both expression of receptor mRNA and response to dopaminergic agents (both observed in Treg only). We turned therefore to receptor function by measuring intracellular levels of cAMP, which is the second messenger acted upon by D1-like receptors (see e.g. 34) , and such experiments unequivocally showed that receptor-second messenger coupling occurs in Treg only (Fig. 7) . We cannot exclude that dopaminergic receptors on Teff may respond, however our results do not support this possibility.
Currently available pharmacological tools do not allow to distinguish between D1 and D5 receptors:
SCH 23390 shows similar affinities for D1 (K i ~0.2 nM) and D5 (K i = 0.3 nM). 35 We therefore tried to obtain some indication about the relative importance of these two subtypes in Treg by using two
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From D2-like selective antagonists which nonetheless clearly differ in their relative affinity for D1 and D5 receptors, namely haloperidol (K i at D1 ~80 nM, and at D5 ~100 nM) and spiperone (K i at D1 ~350 nM, and at D5 ~3500 nM). 35 The affinity ratio spiperone/haloperidol is therefore ~4.4 at D1 and ~35 at D5, and the affinity ratio spiperone/SCH 23390 is ~1750 at D1 and 11667 at D5. In our experiments, the IC 50 s of haloperidol, spiperone and SCH 23390 on DA-induced cAMP increase in Treg were respectively 87.3 nM, 1877 nM and 0.17 nM, with a potency ratio spiperone/haloperidol of ~21.5 and spiperone/SCH 23390 of ~11041. These results, together with the observation that on Treg D1 receptors are less expressed than D5, suggest that D5 receptors are the main responsible for dopaminergic inhibition of Treg function. In any case, in our experimental conditions we could not account for a number of factors possibly influencing receptor response, e.g. high/low affinity state of the receptors, receptor coupling to G proteins, etc., 35 thus our data should be taken only as a preliminary indication. The future availability of new agents with a better D1/D5 selectivity profile will eventually allow to better define the relative role of D1-like receptor subtypes on human Treg.
Dopaminergic modulation of Treg and Teff function
The effects of reserpine and of dopaminergic agents support the existence of a dopaminergic inhibitory loop sustained by endogenous catecholamines regulating Treg function. Dopaminergic effects include inhibition of IL-10 and TGF-β production and impairment of the ability of Treg to suppress Teff proliferation. The effects seem to be selectively exerted on Treg, since in our experiments, reserpine affected neither Teff production of IL-10 or TGF-β, nor Teff proliferation in the absence of Treg. In human T cells DA triggers the production of IL-10. 25 However Teff contain only trace amounts of DA (and of other catecholamines), therefore endogenous autocrine/paracrine loops are unlikely. Reserpine had also no effect on TNF-α or IFN-γ production in Teff/Treg cocultures, suggesting that Treg-induced inhibition of the production of these cytokines is independent from the dopaminergic control of these cells. As in the case of IL-10, also TNF-α production is induced by DA in T lymphocytes. 25 Failure of reserpine to affect TNF-α (and IFN-γ) production in Lymphocyte activation may therefore profoundly affect the response to dopaminergic agents, a phenomenon which could contribute to explain the heterogeneous and sometimes conflicting results so far obtained. 22, 24, 29, 30, 36 Dependence of the functional response upon time of exposure and functional status of the cells has been studied in-depth for noradrenergic pathways. Murine CD4+ effector T cells differentially express β 2 -ARs, both at rest and following activation, with detectable expression on Th1 but not on Th2 cells. 37 Interestingly, although both NE and E inhibit PHA-induced synthesis of IFN-γ by murine immune spleen cells, 38 more IFN-γ is produced by Th1 cells generated from NE-exposed naive T cells, 39 Moreover, exposure of Th1 cells to NE or to the β 2 -AR agonist terbutaline decreases IL-2 production upon the first activation but not upon restimulation. 40 TH-dependent production of catecholamines in human lymphocytes is triggered upon activation, 16 affects activation-dependent apoptosis, 18 and is down-regulated by D1-like receptor activation, 17 an observation which further adds to the complexity of the catecholaminergic network in immune cells. Indeed, it cannot be excluded that catecholamines released by Treg, while suppressing Treg themselves, may also result in direct activation of Teff.
22,25
Clinical implications of dopaminergic modulation of Treg function
Although much investigation is still needed to unravel the complex mechanisms acted upon by catecholamines in the immune system, the results of the present study support dopaminergic D1-like receptor pathways as targets for the functional modulation of human Treg. In view of the key role played by Treg in the control of immune homeostasis, this finding has a potentially very wide array of clinical implications. Hereafter, we will briefly discuss those related to antitumor immunity and to autoimmune disease, since in such conditions the therapeutic use of dopaminergic agents has been often attempted, although with disappointing results. DA has been proposed to regulate malignant cell proliferation and to control immune functions both directly and indirectly (reviewed in 41). More than two decades ago DA was suggested as a novel antitumor agent against e.g. melanoma, 42 however its possible mechanism(s) of action remained ill-defined. 43 Recently, in a mouse model of carcinoma DA improved the antitumor efficacy of cyclophosphamide while reducing its hematotoxicity. 44 Further investigations are needed to confirm those results, as well as to assess their clinical relevance, however it cannot be excluded that DA as an antitumor agent may also act through downregulation of Treg which maintain tolerance towards tumor cells. 45 For personal use only. on September 13, 2017. by guest www.bloodjournal.org From Interestingly, we have recently reported that activation of IFN-Type I receptors effectively induces catecholamine release from activated lymphocytes 46 and we are currently studying the effects of Type I IFNs on human Treg: the hypothesis that the antitumor efficacy of IFN-α 47, 48 may be attributed at least in part to downregulation of Treg function through DA release leading to activation of D1-like receptors is quite intriguing. As for autoimmunity, the involvement of dopaminergic mechanisms has been usually explained taking into account the ability of dopaminergic agonists to suppress the pituitary secretion of prolactin, a hormone which is considered to have a pathogenic role e.g. in rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. 49 However, autoimmune disease seems to be associated with altered brain dopaminergic neurotransmission in animal models, 50 as well as with impaired dopaminergic mechanisms in peripheral lymphocytes, in particular in multiple sclerosis patients. 18, 51 Thus the contribution of dopaminergic pathways to autoimmunity is likely to be more complex than previously thought, involving also peripheral mechanisms. Failure to replicate in clinical trials the usually favourable results obtained with dopaminergic agents in animal models of autoimmune disease could be possibly ascribed also to the still limited comprehension of the contribution of such mechanisms.
Exploitation of endogenous catecholamines in human lymphocytes as novel targets for therapeutic interventions still requires clarification of the functional network sustained by these mediators (Fig.   9 ), which nonetheless could be approached by several different pharmacological strategies.
Lymphocyte catecholamines can be modulated at the following levels: a) intracellular storage (as shown in the present study); b) receptor activation/blockade by selective agonists/antagonists; c) inhibition of catecholamine synthesis (e.g. using the anti-hypertensive agent α-methyl-p-tyrosine, a TH selective inhibitor); d) enhancement of catecholamine synthesis (e.g. using the anti-Parkinson drug L-DOPA, the direct DA precursor). Reserpine is currently used as an anti-hypertensive agent, although its use is limited by a burden of adverse effects. Other therapeutic agents however have been shown at least in vitro to interfere with the storage of catecholamines in lymphocytes, such as tetrabenazine 52 and Type-I IFNs. 46 Interestingly, IFN-β restores dopaminergic signalling in lymphocytes, 51 indicating that its effects on lymphocyte catecholamines is exerted at several levels.
In view of the wide array of dopaminergic and adrenergic agents currently in clinical use for various indications and of their usually favourable therapeutic index, in-depth characterization of these mechanisms in the functional modulation of human lymphocytes could provide the rationale for further investigation examining the therapeutic potential of such agents in a number of major disease conditions.
For 
AJ005353
For personal use only. Table 3 .
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From Table 2 . 
